Centaurus Financial, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Centaurus Financial, Inc.
- $1.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
264Shares Held
59.4MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$378 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$223 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$192 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$105 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$97.5 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.95B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...